ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

STUDY TO KNOW THE INTRAVENOUS OCTEROTIDE EFFICACY IN EARLY VARICEAL REBLEED PREVENTION AFTER SCLEROTHERAPY

Dr. Muhammad Tanveer Sajid, Dr. Mehwish Alamdar, Dr. Maria Khalid

Objective:Objective: To evaluate the efficacy of intravenous octreotide after sclerotherapy in the prevention of early variceal bleeding. Study Design: A descriptive study of the case series. Place and Duration: In the Medical Unit II of Jinnah Hospital Lahore for one year duration from August 2017 to August 2018. Methods: The study included 200 patients with variceal bleeding. All patients received 50 μg of octreotide bolus followed by continuous intravenous infusion of 50 / g / hour and sclerotherapy 12-24 hours later. After sclerotherapy, these 200 cases were continued with intravenous octreotide at 50 μg / hr for 48 hours. All patients were observed for early bleeding findings within 5 days with a history of hematemesis and malena. Results: The mean age of the patients was 41,3 + 9.8. There were 30 (15%) patients, first degree, 78 (39%) patients, second degree and 92 (46%) patients with variceal bleeding. Of the patients, 135 (67.5%) had ascites, and 65 (32.5%) didn't. Hematemesis and malena were present in the distribution of new patients (14%) and in 172 (86%) of them there was no hematemesis / melena. Conclusion: Intravenous octreotide is an effective treatment method to prevent bleeding within 5 days after sclerotherapy in cirrhotic patients. Key words: hepatic cirrhosis, esophageal varices, sclerotherapy, octreotide.

FULL TEXT